Drug Information | Therapeutic Target Database

Drug General Information

Drug ID

D0I6QZ

Drug Name

Org-37663

Indication

Discovery agent [ICD-11: N.A.]

Investigative

[1]

Target and Pathway

Target(s)

Estrogen receptor (ESR)

Target Info

Modulator

[1]

KEGG Pathway

Estrogen signaling pathway

Prolactin signaling pathway

Thyroid hormone signaling pathway

Endocrine and other factor-regulated calcium reabsorption

Proteoglycans in cancer

NetPath Pathway

FSH Signaling Pathway

EGFR1 Signaling Pathway

RANKL Signaling Pathway

Pathway Interaction Database

Regulation of nuclear SMAD2/3 signaling

Signaling events mediated by HDAC Class II

Plasma membrane estrogen receptor signaling

LKB1 signaling events

Regulation of Telomerase

ATF-2 transcription factor network

AP-1 transcription factor network

FOXM1 transcription factor network

Validated nuclear estrogen receptor alpha network

Signaling mediated by p38-alpha and p38-beta

FOXA1 transcription factor network

Reactome

Nuclear signaling by ERBB4

Nuclear Receptor transcription pathway

WikiPathways

Estrogen signaling pathway

Nuclear Receptors Meta-Pathway

Estrogen Receptor Pathway

Signaling by ERBB4

JAK/STAT

Integrated Pancreatic Cancer Pathway

Leptin signaling pathway

miR-targeted genes in muscle cell - TarBase

Integrated Breast Cancer Pathway

Nuclear Receptors

References

REF 1

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.Arthritis Rheum.2010 Feb;62(2):351-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.